Asset
Upleganan
Spero Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03792308 | phase1 | completed | 2018-12-18 | 2019-12-23 | Spero Therapeutics | A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers |
| NCT04865393 | phase1 | completed | 2021-06-08 | 2021-12-01 | Spero Therapeutics | Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function |
| NCT04868292 | phase1 | completed | 2021-06-03 | 2021-09-16 | Spero Therapeutics | Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.